Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab effect on microglial activation in MS
NCT03983252Phase 2Withdrawn
- Sponsor
- Brigham and Women's Hospital
- Start
- Dec 2021
- Primary completion
- May 2024
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in multiple sclerosis (MS), sponsored by Brigham and Women's Hospital. Planned start Dec 2021; status: withdrawn.
02
Drugs
alemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03983252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03983252.